Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NSAV... .0005... News...
NSAV ANNOUNCES COMPLETION OF ANTI-REVERSE SPLIT AMENDMENT TO ARTICLES OF INCORPORATIONPress Release | 01/08/2021
Net Savings Link, Inc. (OTC: NSAV), a medical cannabis technology and software company, today announced that the Company has finalized an amendment to its Articles of Incorporation, which would prevent NSAV from enacting a reverse stock split. The amended articles are now on file with the state of Colorado and can be viewed by the public at the Colorado Secretary of States website. The Company believes this amendment should finally put an end to all rumors that NSAV will reverse split its shares.
NSAV further announced that no dilution of its shares is taking place and that the Company has reached its maximum in terms of its Authorized Shares.
James Tilton, president of NSAV stated, I am truly proud of our management and legal team for completing this Anti-Reverse Stock Split Amendment on time and at Warp Speed. As the Companys senior officer, I realize the importance of keeping promises to our loyal NSAV shareholders and getting the job done correctly and on time. With this amendment, all of our loyal current and future shareholders can put their minds at ease.
https://www.otcmarkets.com/stock/NSAV/news/NSAV-ANNOUNCES-COMPLETION-OF-ANTI-REVERSE-SPLIT-AMENDMENT-TO-ARTICLES-OF-INCORPORATION?id=285615
OMID... Busted the 50dma and the 100dma and resistance #1 to boot... Now, lets make that support and bust R2... GidDy uP OMID...
https://schrts.co/fiCFQnPK
OMID... Busted the 50dma and the 100dma and resistance #1 to boot... Now, lets make that support and bust R2... GidDy uP OMID...
https://schrts.co/fiCFQnPK
DFCO... another Form 4... GidDy uP DFCO...
https://www.otcmarkets.com/filing/html?id=14597312&guid=IUCqUKwBhMdta8h
DFCO... .29...Daily psar flipped to the bullish side today...
https://schrts.co/sgTEzajf
WHEN... .0005s going...
NSAV News...
NSAV ANNOUNCES IDENTITY OF DUTCH CANNABIS COMPANY ACQUISITION TARGETPress Release | 01/04/2021
Net Savings Link, Inc. (OTC: NSAV), a medical cannabis technology and software company, today announced the identity of the Dutch cannabis company that it is in advanced negotiations to acquire. The cannabis company, Greenmill Growlabs
( http://dutchgrowlabs.com ) , is based in the Netherlands and offers a full range of agricultural and CBD products under its own brand name. According to Greemill management, it is profitable, with annual sales of $1 million and a net profit of $150,000.
The management of NSAV believes there is a tremendous potential for growth with Greenmill, both in the Netherlands and across Europe.
https://www.otcmarkets.com/stock/NSAV/news/NSAV-ANNOUNCES-IDENTITY-OF-DUTCH-CANNABIS-COMPANY-ACQUISITION-TARGET?id=285007
SSOK... .003...
DFCO...
December 28 – OTC Markets Group Welcomes New OTCQB Companies
https://www.otcmarkets.com/stock/DFCO/news/OTC-Markets-Group-Welcomes-New-OTCQB-Companies--December-28?id=284519
DFCO... News Link... uPlisted to otcqb...
https://www.otcmarkets.com/stock/DFCO/news/Dalrada-Financial-Corporation-Announces-Up-List-To-OTCQB-Market?id=284278
DFCO... .22... RSI has Cooled off and Slow Stoastics bottomed out, ready to curl back to the uPside... GidDy uP DFCO...
https://schrts.co/ZrtzPAup
DFCO... .22... RSI has Cooled off and Slow Stoastics bottomed out, ready to curl back to the uPside...
https://schrts.co/ZrtzPAup
Interesting...Universal broadband goals could be achieved more quickly with more coordination between different levels of government, and with the private sector.
https://policyoptions.irpp.org/magazines/december-2020/rural-broadband-connectivity-hinges-on-private-public-collaboration/
LOL... GidDy uP DFCO...
GCGX....0006 Pink current Marijuana... Look at that accumulation line spike with the Williams at -57, ready to test resistance #1 again...
http://schrts.co/EjBIVRma
Lifetime Warranty...
https://indulgeoils.com/
https://www.globenewswire.com/news-release/2020/10/27/2115371/0/en/Global-Consortium-Inc-Issues-Corporate-Update.html
Indulge OilsIndulge Oils
FEEL, ACT & VAPE LIKE A MILLION BUCKS.
Without paying it. Try the Oil today.
GlobeNewswire News RoomGlobeNewswire News Room
Global Consortium, Inc., Issues Corporate Update
COCONUT CREEK, Fla., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Global Consortium, Inc., (OTCPINK: GCGX) would like to announce major changes taking place within...
stockcharts.comstockcharts.com
GCGX - Global Consortium Inc.
SharpChart from StockCharts.com (25 kB)
https://stockcharts.com/c-sc/sc?s=GCGX&p=D&b=5&g=0&id=p50002229267
GCGX....0006... Look at that accumulation line spike with the Williams at -57, ready to test resistance #1 again...
http://schrts.co/EjBIVRma
Pink current Marijuana...
Lifetime Warranty...
https://indulgeoils.com/
https://www.globenewswire.com/news-release/2020/10/27/2115371/0/en/Global-Consortium-Inc-Issues-Corporate-Update.html
Indulge OilsIndulge Oils
FEEL, ACT & VAPE LIKE A MILLION BUCKS.
Without paying it. Try the Oil today.
GlobeNewswire News RoomGlobeNewswire News Room
Global Consortium, Inc., Issues Corporate Update
COCONUT CREEK, Fla., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Global Consortium, Inc., (OTCPINK: GCGX) would like to announce major changes taking place within...
stockcharts.comstockcharts.com
GCGX - Global Consortium Inc.
SharpChart from StockCharts.com (25 kB)
https://stockcharts.com/c-sc/sc?s=GCGX&p=D&b=5&g=0&id=p50002229267
GCGX... .0006 pink current Marijuana...
Lifetime Warranty...
https://indulgeoils.com/
https://www.globenewswire.com/news-release/2020/10/27/2115371/0/en/Global-Consortium-Inc-Issues-Corporate-Update.html
Look at that accumulation line spike with the Williams at -57, ready to test resistance #1 again...
http://schrts.co/EjBIVRma
Indulge OilsIndulge Oils
FEEL, ACT & VAPE LIKE A MILLION BUCKS.
Without paying it. Try the Oil today.
GlobeNewswire News RoomGlobeNewswire News Room
Global Consortium, Inc., Issues Corporate Update
COCONUT CREEK, Fla., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Global Consortium, Inc., (OTCPINK: GCGX) would like to announce major changes taking place within...
stockcharts.comstockcharts.com
GCGX - Global Consortium Inc.
SharpChart from StockCharts.com (25 kB)
https://stockcharts.com/c-sc/sc?s=GCGX&p=D&b=5&g=0&id=p50002229267
HJLI...November 23, 2020...
Hancock Jaffe's VenoValve(R) Results Featured in Journal of Vascular Surgery Venous and Lymphatic Disorders
Preliminary First-in-Human Study Results Published in Peer-Reviewed Journal
IRVINE, CA / ACCESSWIRE / November 23, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the Journal of Vascular Surgery Venous and Lymphatic Disorders, published a paper featuring interim results from the VenoValve first-in-human trial. The article entitled "Human Trial Using the Novel Bioprosthetic VenoValve in Patients with Chronic Venous Insufficiency" is published online on the journal's website. This article emanated from a presentation on the VenoValve given at Southern Association of Vascular Surgery, January 8, 2020 conference in Palm Beach, Florida by Dr. Jorge Ulloa, the principal investigator for the study as well as President of Vascular Society of Colombia.
Dr. Marc Glickman, HJLI's Senior Vice President and Chief Medical Officer and co-author of the article stated, "JVS represents the pinnacle of peer-reviewed journals for vascular surgery. The journal focuses on latest and most innovative devices and treatments for vascular disease and is widely read by vascular surgeons and health care professionals. We are thrilled to have the opportunity to inform the medical community about our progress with the VenoValve".
HJLI expects to release additional updated results from the VenoValve first-in-human trial throughout the fourth quarter as additional patients complete the one-year study. The first phase of the Colombian study, during which all 11 patients will have achieved the important one-year milestone, will conclude in December of 2020. Preparations have begun for HJLI to file the IDE application with the U.S. Food and Drug Administration for the VenoValve U.S. Pivotal trial, which the company expects to file in Q1 of 2021.
The VenoValve is a porcine based bioprosthetic device that is implanted in the deep femoral vein of the leg to treat a condition called Chronic Venous Insufficiency ("CVI"). CVI occurs when the valves in the veins of the leg are injured or destroyed, causing blood to flow backwards ("reflux"), and increasing pressure in the veins of the leg ("venous hypertension"). Deep venous CVI is a serious condition, often resulting in debilitating pain, swelling, and open sores (venous ulcers) on the lower leg. The VenoValve has demonstrated the potential to improve reflux, alleviate disease manifestations, reduce pain, promote venous ulcer healing, and significantly improve the quality of the lives of the 8 VenoValve patients that have completed the study to date.
Approximately 2.4 million people in the U.S. suffer from CVI due to reflux in the deep venous system. Estimates indicate that direct medical costs from CVI in the U.S. exceed $38 Billion a year. There are currently no FDA approved devices, or effective treatments for deep venous CVI.
The Journal of Vascular Surgery: Venous and Lymphatic Disorders is the premier international journal of medical, endovascular, and surgical management of venous and lymphatic disorders. An abstract of the article can be accessed here: https://www.jvsvenous.org/article/S2213-333X(20)30636-3/fulltext#secsectitle0010 with public access to the full article soon to follow.
https://www.otcmarkets.com/stock/HJLI/news/story?e&id=1749975